Downloading...
Download

Coronastocks

Corona death analyses in GermanyWelcome to my Corona Death Analysis *Note because the chart was inserted as an image, the scaling may have shifted slightly, simply scale at the right edge until the orange zero matches the zero line of the chart. First of all, I know Corona is a delicate subject and also that I analyze the deaths here seems to work a macabre, but the fact is that the numbers are rising and this can have an impact on the German economy, this analysis serves as a complement to my DAX short analysis and is purely scientific nature. The Dax analysis can be found here (German Only) Let's get to the analysis: As we can see from the chart, deaths increased rapidly between January and February, reaching a high of ca 1138. In February, a bearish SKS formed at the high which had also already reached its target of 371 deaths. This target line is very often reached again after the Unterstreiten in later upward movements or correction phases and serves us thus as a first "target line" Furthermore, we can take from the chart an ABC Correct which has the following death numbers as a target. Target 1 435 Target 2 705 Target 3 900 Target 4 1451 Target 5 1846 Here the death number of 900 is to be seen as the first strong resistance. At 1451 I expect the end of the rising numbers for the first time, whereas 1846 deaths would be the maximum and at the latest here a trend reversal should take place. If you liked this idea, I would be pleased about a click on the Like button ;) If you have any questions, suggestions or a different opinion, don't be afraid to use the comment function. Thanks a lot Disclaimer: Please keep in mind that this is a pure analysis and only reflects what my eye shows me ;) This analysis is for informational purposes only and is scientific in nature. This analysis is not based on any fundamental data! This analysis is not an investment advice and should not be considered as a buy, sell or hold signal. Always do your own research before investing and seek the advice of a qualified person. I am not an investment advisor or similar and do not make any investment recommendation here.
TSE:5909Long
by Highrisk221
Testing kits on Delta VariantFundamental Quidel: a manufacturer of diagnostic products, frequently rises or sinks in response to developments in the coronavirus pandemic, as a big part of their revenue comes from its COVID-19 testing kits. As the Delta Variant is worrying countries around the globe, QDEL will be interesting to watch. Technical Analysis As you can see in the weekly chart, the blue horizontal line which is approximately $150 was tested multiple times, is now also coinciding with the 50ema, which has worked well as support. A potential target could be in place, as there is still a downtrend from the Pfizer Vaccine initial news of 95% efficacy.
NASDAQ:QDEL
by dorfmanmaster
1
VXRT Vaxart Covid-19, Uptrend and Price TargetVXA-CoV2-1, Vaxart's experimental treatment for Covid-19 is unique in that it's a pill, not an injection. A pill would certainly be easier from a distribution and administration standpoint but also to get higher vaccination rates. On May 3, Vaxart's treatment showed demonstrable CD8 T-cell responses, but didn't produce high levels of neutralizing antibodies in trial participants, which makes it less efficient than traditional COVID-19 injections. On 6/11/2021 Piper Sandler brokerage Initiated Coverage with Overweight rating and a Price Target of $18.00 From a technical analysis point of view, the stock looks in an uptrend.
VLong
by TopgOptions
Why $IFMK Skyrocketed in February? indoor dining shutdownsWhy $IFMK Skyrocketed in February There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. $IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month. iFresh Inc is an Asian/Chinese grocery supermarket chain in the North-Eastern U.S. providing food and other merchandise hard to find in mainstream grocery stores. The company generates a majority of its revenue from its retail segment. The other positive factor for the $IFMK is the surging Food delivery in NYC as indoor dining shutdowns continue (based out of nyc), due to covid 19. www.benzinga.com twitter.com
I
by AlenCiken
Corona(Covid 19 vaccine) stock that can explode in 2021A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed? over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race. Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and BioNTech. In fact, over 30% of Vaxart stock has been sold short. Vaxart claims to have created an experimental coronavirus vaccine in the form of an oral tablet. One could potentially self-administer the vaccine pill, which is stable at room temperature. This would allow patients to order the vaccine online and have it delivered for at-home use. At the moment, Vaxart's experimental coronavirus vaccine is only in phase 1 clinical trials, with a new data readout expected by next week. Unfortunately, it's impossible to conclude how the experimental vaccine will work on humans from animal models. Hence, the candidate's phase 1 data release will likely be a make-or-break moment for Vaxart. Vaxart is under investigation by both the U.S. Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) for insider trading and inaccurate statements regarding its role in Operation Warp Speed (OWS). Even though Vaxart has more than $133 million in cash and equivalents with no debt whatsoever, that's not nearly enough to move forward. Right now, it could cost billions of dollars to run a potential coronavirus vaccine through clinical trials involving tens of thousands of participants. The company will likely sell more stock to pay for its research and development (R&D) expenses or apply for grant funding -- just to stay afloat. Vaxart is far riskier than the other coronavirus vaccine drugmakers out there. Its corporate conduct is under federal investigation, and its vaccine candidate is in far too early a stage to draw any definitive conclusions about. With a market cap just south of $1 billion, it will undoubtedly become a very undervalued stock if it can bring a coronavirus vaccine to market. Moderna, which has done so, projects $11.7 billion in revenue from its mRNA-1273 vaccine alone. However, the probability of Vaxart achieving anything remotely similar is up for debate. Short-sellers and passionate bulls will be arguing over the stock for the next year. If you believe in Vaxart's science and have the stomach for a roller-coaster ride, then go for it.
V
by AlenCiken
Adamis Surges After Submitting Covid Drug to FDAAdamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls (CMC) and Clinical aspects to be included in the IND. The Company plans to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol. Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. finance.yahoo.com
A
by AlenCiken
1
MRNA HOLD BULLISHI am not swinging this one, even though it is tempting. I recently sold NVAX at 15% profit, and due to strong correlation with MRNA I was considering selling my MRNA as well, in which case I would have made 14% right now. However, I decided to hold because of 2 reasons : 1) AstraZeneca just took a major hit (if you don't know about it, catch up on the news). This takes out a bit of competition and investor fund distribution might come this way 2) MRNA shows a strong uptrend with good momentum, and that is mainly why I will HOLD it for longer term. Hit like if you found this helpful and interesting. Thanks, E
NASDAQ:MRNA
by BlockTechEv
9
$ADGS Potential R/M with new Officer listed LF, PPS Target $50+$ADGS New CEO listed and $200,000 in Taxes paid to get the company up to date on filings. Usually when this happens there's a good reason for it such as a potential R/M and a big one. So far there's been several Xu connections; One to a medical company that is dealing with the Corona-virus, a large Burger Franchise overseas and a large tech company. There is no concrete connection yet, but we have loaded and will wait for more filings. Personal target based on the S/S $50+
ALong
by StockGuild